A modern view of the immunopathogenesis of chronic hepatitis B

DOI: https://dx.doi.org/10.18565/epidem.2020.10.4.73-9

Omarova Kh.G., Makashova V.V., Ponezheva Zh.B., Khokhlova O.N.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
Chronic HBV infection is a dynamic process that reflects the interaction between HBV replication and the host immune response. The data available in the literature show that in chronic hepatitis B, it is precisely the quantitative composition and functions of innate immune cells which have a pronounced effect on the virus. A deep insight into the immunopathogenetic mechanisms caused by individual antigenic HBV components that cause both chronic hepatitis B and its adverse outcomes will serve as the basis for using prognostically significant methods for immunodiagnosis, as well as for effective treatment and prevention of the disease.


1. World Health Organization. Global hepatitis report, April 2017; 83. https://www.who.int/hepatitis/publications/global-hepatitis-report 2017/en/

2. World Health Organization. Hepatitis B Fact Sheet. http://www.who. int/mediacentre/factsheets/fs204/en/

3. EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017; 67: 370–98. https://doi.org/10.1016/ j.jhep.2017.03.021

4. Жданов К.В., Лобзин Ю.В., Гусев Д.А., Козлов К.В. Вирусные гепатиты. СПб: Фолиант, 2011. 304 с.

Zhdanov K.V., Lobzin Yu.V., Gusev D.A., Kozlov K.V. [Viral hepatitis]. Saint-Petersburg: Folio, 2011. 304 p. (In Russ.).

5. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167–85.

6. Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546–55.

7. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 288 с.

Abdurakhmanov D.T. [Сhronic hepatitis В and D]. Мoscow: GEOTAR-Media, 2010. 288 р. (In Russ.).

8. Baumert T.F., Thimme R., von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 2007; 13: 82–90. https://doi.org/ 10.3748/wjg.v13.i1.82

9. Balmasova I.P., Yushchuk N.D., Mynbayev O.A., Alla N.R., Malova E.S., Shi Z., Gao K.I. [Immunopathogenesis of chronic hepatitis B]. World J. Gastroenterol. 2014; 20 (39): 14156–71. doi: 10.3748/wjg.v20.i39.14156

10. Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol. Commun. 2018; 3(1): 8–19. doi:10.1002/hep4.1281

11. Seeger C., Mason W.S. Molecular biology of hepatitis B virus infection J. Virol. 2015; 479–480: 672–86. https://doi.org/10.1016/j.virol.2015.02.031

12. Lee J., Shin M.K., Lee H.J., Yoon G., Ryu W.S. Three novel cis-acting elements required for efficient plus-strand DNA synthesis of the hepatitis B virus genome. J. Virol. 2004; 78: 7455–64. doi: 10.1128/JVI.78.14.7455-7464.2004

13. Bertoletti A., Kennedy P.T. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol. Immunol. 2015; 12(3): 258–63. doi: 10.1038/cmi.2014.79

14. Said Z.N. An overview of occult hepatitis B virus infection. World. J. Gastroenterol. 2011; 17(15): 1927–38. doi: 10.3748/wjg.v17.i15.1927.

15. Wong D.K., Huang F.Y., Lai C.L., Poon R.T, Seto W.K., Fung J. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829–36. doi: 10.1002/hep.24551

16. Roseman A.M., Borschukova O., Berriman J.A., Wynne S.A., Pumpens P., Crowther R.A. Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J. Mol. Biol. 2012; 423(1): 63–78. doi: 10.1016/j.jmb.2012.06.032.

17. Block T.M., Mehta A.S., Blumberg B.S., Dwek R.A. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity? DNA Cell Biol. 2006; 25 (3):165–70. doi: 10,1089/dna.2006.25.165

18. Li L., Liu M., Cheng L.W., Gao X.Y., Fu J.J., Kong G. et al. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand. J. Immunol. 2013; 78(5): 439–46. doi: 10.1111/sji.12099

19. Buchmann P., Dembek C., Kuklick L., Jäger C., Tedjokusumo R., von Freyend M.J. et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31(8):1197–203. doi: 10.1016/ j.vaccine.2012.12.074

20. You J., Sriplung H., Geater A., Chongsuvivatwong V., Zhuang L., Chen H.Y. et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol. 2008; 14(7): 1112–9. doi: 10.3748/wjg.14.1112

21. Block T.M., Guo H., Guo J.T. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 2007; 11(4): 685–706. doi: 10.1016/j.cld.2007.08.002

22. Shi Y.H., Shi C.H. Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol. 2009; 15(25): 3099–105. doi: 10.3748/wjg.15.3099

23. Li N., Li Q., Qian Z., Zhang Y., Chen M., Shi G. Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem. Biophys. Res. Commun. 2009; 390(3):.630–5. doi: 10.1016/j.bbrc.2009.10.018

24. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214(2): 199–210. doi: 10,1002/path.2277

25. Shi F., Zhang J.Y, Zeng Z., Tien P., Wang F.S. Skewed ratios between CD3(+) T cells and monocytes are associated with poor prognosis in patients with HBV-related acute-on-chronic liver failure. Biochem. Biophys. Res. Commun. 2010; 402(1): 30–6. doi: 10.1016/j.bbrc.2010.09.096

26. Feitelson M.A., Reis H.M.G.P.V., Liu J., Lian Z., Pan J. Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenezis. Frontiers in Bioscience 2005; 10: 1558–72. doi: 10,2741/1640

27. Zhang Z., Zhang J.Y., Wang L.F., Wang F.S. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 2012; 27(2): 223–30. doi: 10.1111/j.1440-1746. 2011.06940.x

28. Kim J.Y., Song E.H., Lee H.J., Oh Y.K., Choi K.H., Yu D.Y. et al. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J. Mol. Biol. 2010; 397(4): 917–31. doi: 10.1016/j.jmb.2010.02.016

29. Dunn C., Brunetto M., Reynolds G., Christophides T., Kennedy P.T., Lampertico P. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 2007; 204(3): 667–80. doi: 10.1084/jem.20061287

30. Ratnam D., Visvanathan K. New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. Hepatol. Int. 2008; 2(Suppl.1): 12–8. doi: 10.1007/s12072-008-9067-0

31. Chen J., Wu M., Zhang X., Zhang W., Zhang Z., Chen L. et al. Hepatitis B virus polymerase impairs interferon-α-induced STAT activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 2013; 57(2): 470–82. doi: 10.1002/hep.26064

32. Ito T., Kanzler H., Duramad O., Cao W., Liu Y.J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006; 107(6): 2423–31. DOI: 10,1182/кровь-2005-07-2709

33. Ma Y.J., He M., Han J.A., Yang L., Ji X.Y. A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand. J. Immunol. 2013; 78(4): 387–93. doi: 10.1111/sji.12097

34. Хохлова О.Н., Серебровская Л.В., Ходжибеков Р.Р., Гезахегне Д.Б., Кожевникова Г.М., Покровский В.В., Рейзис А.Р. Роль плазмоцитоидных дендритных клеток как новых иммуноцитов в патогенезе ХГС, ХГВ И ВИЧ-инфекции. Инфекционные болезни 2016; 14(4): 31–6.

Khokhlova O.N., Serebrovskaya L.V., Khodzhibekov R.R., Gezakhegne D.B., Kozhevnikova G.M., Pokrovskiy V.V., Reizis A.R. [The role of plasmacytoid dendritic cells as a new immune cells in the pathogenesis of chronic hepatitis C, chronic hepatitis B and HIV]. Infektsionnye bolezni 2016; 14(4): 31–6. (In Russ.).

35. Woltman A.M., Ter Borg M.J., Binda R.S., Sprengers D., von Blomberg B.M., Scheper R.J. et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir. Ther. 2009; 14(6): 809–18. doi: 10,3851/IMP1295

36. Sun H.H., Zhou D.F., Zhou J.Y. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. J. Med. Virol. 2016; 88: 13–20. doi:10.1002/jmv.24306

37. Duan X.Z., Wang M., Li H.W., Zhuang H., Xu D., Wang F.S. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J. Clin. Immunol. 2004; 24(6): 637–46. DOI: 10.1007/s10875-004-6249-y

38. Opden Brouw M.L., Binda R.S., van Roosmalen M.H., Protzer U., Janssen H.L., van der Molen R.G., Woltman A.M. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126(2): 280–9. doi: 10.1111/j.1365-2567.2008.02896.x

39. Сепиашвили Р.И., Балмасова И.П., Кабанова Е.В., Малова Е.С., Славянская Т.А. Вирус гепатита В: биология, иммунопатогенез, система NK/NKT в вирусной персистенции. Журн. микробиол., эпидемиол., иммунол. 2006; (6): 76–83. PMID: 17163145

Sepiashvili R.I., Balmasova I.P., Kabanova E.V., Malova E.S., Slavianskaya TA. [Hepatitis B virus: biology, immunopathogenesis, NK/NKT system in viral persistence]. Zhurnal mikrobiologii, èpidemiologii i immunobiologii 2006; (6): 76–83. (In Russ.).

40. Lang K.S., Georgiev P., Recher M., Navarini A.A., Bergthaler A., Heikenwalder M. et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 2006; 116(9): 2456–63. DOI: 10,1172/JCI28349

41. Moretta A., Marcenaro E., Parolini S., Ferlazzo G., Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death. Differ. 2008; 15(2): 226–33. DOI: 10,1038/sj.cdd.4402170

42. Stoop J.N., Woltman A.M., Biesta P.J., Kusters J.G., Kuipers E.J., Janssen H.L., van der Molen R.G. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 2007; 46(3): 699–705. DOI: 10.1002/hep.21761

43. Jinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N. et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4+CD25+ T cells with PD-1-dependent regulatory activities. Immunology 2007; 120(1): 73–82. DOI: 10,1111/j.1365-2567.2006.02479.x

44. Weng P.J., Ying H., Hong L.Z., Zhou W.H., Hu Y.R., Xu C.H. An analysis of CD3+CD56+ lymphocytes and their subsets in the peripheral blood of patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2008; 16(9): 654–6.

45. Rauch A., Laird R., McKinnon E., Telenti A., Furrer H., Weber R. et al. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens 2007; 69 (Suppl 1): 237–40. DOI: 10,1111/j.1399-0039.2006.773_4.x

46. Peng G., Li S., Wu W., Sun Z., Chen Y., Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008; 123(1): 57–65. DOI: 10.1111/j.1365-2567.2007.02691.x

47. Zhang L., Zhao Y.. The regulation of Foxp3 expression in regulatory CD4(+) CD25(+) T cells: multiple pathways on the road. J. Cell Physiol. 2007; 211(3): 590–97. DOI: 10.1002/ jcp.21001

48. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D. et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445(7130): 931–5. DOI: 10.1038/nature05478

49. Manigold T., Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect. Dis. 2007; 7(12): 804–13. DOI: 10.1016 / S1473-3099 (07)70289-X

50. Guo J.C., Bao J.F., Chen Q.W., Li X.O., Shi J.P., Lou G.Q. et al. Level of serum and liver tissue TGF-beta1 in patients with liver fibrosis due to chronic hepatitis B. Zhonghua Shiyan He Linchuangbingduxue Zazhi 2008; 22(5): 354–7.

51. Fallarino F., Grohmann U., You S., McGrath B.C., Cavener D.R., Vacca C. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006; 176(11): 6752–61. DOI: 10.4049/ jimmunol.176.11.6752

52. Aalaei-Andabili S.H., Alavian S.M. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine 2012; 30(38): 5595–602. doi: 10.1016/j.vaccine.2012.06.063

53. Feng I.C., Koay L.B., Sheu M.J., Kuo H.T., Sun C.S., Lee C. et al. HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J. Biomed. Sci. 14(this issue), doi 10.1007/s11373-006-9129-z

54. Shimizu Y. T-cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World. J. Gastroenterol. 2012; 18(20): 2443–51. Doi: 10.3748/wjg.v18.i20.2443

55. Chen J., Wang X.M., Wu X.J., Wang Y., Zhao H., Shen B., Wang G.Q. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm. Res. 2011; 60(1): 47–53. doi: 10.1007/ s00011-010-0233-1

56. Nan X.P., Zhang Y., Yu H.T., Li Y., Sun R.L., Wang J.P., Bai X.F. Circulating CD4+CD25 high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. Viral Immunol. 2010; 23(1): 63–70. doi: 10.1089/vim.2009.0061

57. Zhang G.L., Xie D.Y., Lin B.L., Xie C., Ye Y.N., Peng L. et al. Imbalance of interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-on-chronic liver failure. J. Gastroenterol. Hepatol. 2013; 28(3): 513–21. doi: 10.1111/jgh.12082

58. Kitani A., Xu L. Regulatory T cells and the induction of IL-17. Mucosal Immunol. 2008; 1(Suppl 1): S43–S46. doi: 10.1038/mi.2008.51

59. Zhang G.L., Xie D.Y., Ye Y.N., Lin C.S., Zhang X.H., Zheng Y.B. et al. High level of IL-27 positively correlated with Th17 cells may indicate liver injury in patients infected with HBV. Liver Int. 2014; 34(2): 266–73. doi: 10.1111 /liv.12268

60. Zerbini A., Pilli M., Boni C., Fisicaro P., Penna A., Di Vincenzo P. et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134(5): 1470–81. doi: 10.1053/j.gastro.2008.02.017

About the Autors

Khadizhat G. Omarova, Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: omarova71@inbox.ru; ORCID: http://orcid.org/0000-0002-9682-2230
Prof. Vera V. Makashova, MD, Leading Researcher, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Well-Being, Moscow, Russia; е-mail: veramakashova@yandex.ru; ORCID: https://orcid.org/0000-0002-0982-3527
Zhanna B. Ponezheva, MD, Head, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: doktorim@mail.ru; ORCID: https://orcid.org/0000-0002-6539-4878
Olga N. Khokhlova, Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Well-Being, Moscow, Russia; е-mail: x.olia79@mail.ru ORCID: https://orcid.org/0000-0001-9736-4043

Similar Articles

Бионика Медиа